A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1)

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).

Study Overview

• Status: Active, not recruiting
• Conditions: Systemic Lupus Erythematosus; Diffuse Cutaneous Systemic Sclerosis; Lupus Nephritis; Idiopathic Inflammatory Myopathies
• Intervention / Treatment: Biological: CNTY-101; Drug: Lymphodepleting Chemotherapy; Biological: IL-2

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • Keck School of Medicine of University of Southern California
    • Sacramento, California, United States, 957817
      • UC Davis
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Lurie Children's; Northwestern Medicine - Northwestern Medical Group
  • Texas
    • Houston, Texas, United States, 77030
      • Texas Children's Hospital
  • Utah
    • Salt Lake City, Utah, United States, 84113
      • Primary Children's Hospital
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

General Inclusion Criteria:

1. 17 years of age and older.
2. Participants must have adequate organ function as defined in the protocol.

SLE/LN-specific Inclusion Criteria:

1. Participants must have a diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus for at least 6 months.
2. Participants must have current or history of elevated anti-double stranded deoxyribonucleic acid (anti-dsDNA), anti-Smith, anti-histone, and/or anti-nucleosome antibodies.

SLE-specific Inclusion Criteria:

1. Participants who have:

1. A Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥8 (including at least 4 points from non-laboratory assessments; excluding alopecia, mucosal ulcers, and fever) and at least 2 British Isles Lupus Assessment Group B (BILAG B) organ system scores and/or
2. At least one British Isles Lupus Assessment Group A (BILAG A) organ system score, including cardiac (peri- or myocarditis), respiratory (pleuritis or lung involvement), vascular and renal.

LN-specific Inclusion Criteria:

1. Participants with active, biopsy-proven, proliferative LN Class III or IV, either with or without the presence of class V, according to the 2018 revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria. Biopsy must be within 12 months prior to Screening or during Screening.

IIM-specific Inclusion Criteria:

1. Classification of IIM (juvenile-onset IIM may be included):

1. For Dermatomyositis (DM), meet 2017 American College of Rheumatology/European Alliance of Associations of Rheumatology (ACR/EULAR) diagnostic criteria for definite or probable DM.
2. For participants with anti-synthetase syndrome (ASyS), meet Classification Criteria for anti-synthetase syndrome per the Classification Criteria for Anti-Synthetase Syndrome (CLASS) Project with a positive tRNA synthetase autoantibody at Screening or per medical history.
3. For Polymyositis (PM)/ necrotizing myopathy (NM), meet 2017 ACR/ EULAR classification criteria for definite or probable PM/NM and meet one of the following criteria:

i. Positive myositis specific antibody (MSA) at Screening or per medical history or ii. Muscle biopsy at Screening or per medical history available for review

DcSSc-specific Inclusion Criteria:

1. Meets the 2013 ACR/EULAR criteria for SSc with a total score of ≥9.
2. Meets criteria for DcSSc, including skin involvement proximal to the elbow and/or knee.
3. mRSS units ≥15 at Screening; for participants agreeing to biopsy, skin thickening from SSc in the forearm suitable for biopsy.

Exclusion Criteria:

General Exclusion Criteria:

1. Participants on hemodialysis.
2. Other comorbid conditions as defined in the protocol.
3. History of allogeneic bone marrow/hematopoietic stem cell or solid organ transplant at any time. History of autologous stem cell transplant >100 days prior to Screening is allowed.
4. Recent or clinically significant central nervous system (CNS) disease, including but not limited to cerebrovascular accident, epilepsy, severe brain injury, dementia, Parkinson's disease, cerebellar disease, seizures, organic brain syndrome, lupus headache, or psychosis at any time prior to study.
5. Thromboembolic events within last 12 months.
6. Participants with severe hepatic dysfunction, defined as grade C-Child-Pugh.

SLE-specific Exclusion Criteria:

1. Participants with BILAG A for neuropsychiatric SLE.
2. Any current, acute, and severe lupus-related flare that needs immediate treatment.
3. Drug-induced SLE rather than idiopathic SLE.
4. Participants with a diagnosis of LN Classes III, IV, V, or VI on the most current biopsy according to the 2018 revised ISN/RPS criteria.
5. Participants with estimated glomerular filtration rate (eGFR) <45 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) (measured by Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation) or serum creatinine >2.5 milligrams per deciliter (mg/dL).

LN-specific Exclusion Criteria:

1. Participants with BILAG A for neuropsychiatric SLE.
2. Any severe lupus-related flare such as acute CNS lupus (eg, psychosis, seizure), catastrophic antiphospholipid syndrome, or rapidly progressive glomerulonephritis that, in the opinion of the Investigator, would cause an unacceptable safety risk.
3. Drug-induced SLE rather than idiopathic SLE.
4. Participants with predominantly LN Class V, or Class VI on the most recent biopsy according to the 2018 revised ISN/RPS criteria.
5. Participants with estimated glomerular filtration rate <30 mL/min/1.73 m^2 (measured by Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation) or serum creatinine >2.5 mg/dL.

IIM- specific Exclusion Criteria:

1. Participants on hemodialysis or estimated glomerular filtration rate <45 mL/min/1.73 m^2 (measured by Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation) or serum creatinine >2.5 mg/dL.
2. Have severe muscle damage as defined in the protocol.
3. Participants with ILD will be excluded if there is severe end stage lung disease as defined in the protocol.

DcSSc-specific Exclusion Criteria

1. Participants on hemodialysis or estimated glomerular filtration rate <45 mL/min/1.73 m^2 (measured by Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation) or serum creatinine >2.5 mg/dL.
2. Participants with ILD will be excluded if there is severe end stage lung disease as defined in the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: CNTY-101 in SLE Participants; During Part 1 (Dose Confirmation Phase), participants with SLE will undergo lymphodepleting chemotherapy (LDC) followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2). After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the recommended phase 2 regimen (RP2R) confirmed during Part 1.	Biological: CNTY-101; CNTY-101 cells for intravenous (IV) infusion; Drug: Lymphodepleting Chemotherapy; LDC as prespecified in the protocol.; Biological: IL-2; IL-2 subcutaneous (SC) injection
Experimental: Arm B: CNTY-101 in LN Participants; During Part 1 (Dose Confirmation Phase), participants with LN will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2. After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1.	Biological: CNTY-101; CNTY-101 cells for intravenous (IV) infusion; Drug: Lymphodepleting Chemotherapy; LDC as prespecified in the protocol.; Biological: IL-2; IL-2 subcutaneous (SC) injection
Experimental: Arm C: CNTY-101 in IIM Participants; During Part 1 (Dose Confirmation Phase), participants with IIM will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2. After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1.	Biological: CNTY-101; CNTY-101 cells for intravenous (IV) infusion; Drug: Lymphodepleting Chemotherapy; LDC as prespecified in the protocol.; Biological: IL-2; IL-2 subcutaneous (SC) injection
Experimental: Arm D: CNTY-101 in DcSSC Participants; During Part 1 (Dose Confirmation Phase), participants with DcSSC will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2. After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2. During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1.	Biological: CNTY-101; CNTY-101 cells for intravenous (IV) infusion; Drug: Lymphodepleting Chemotherapy; LDC as prespecified in the protocol.; Biological: IL-2; IL-2 subcutaneous (SC) injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs	Up to 29 days
Percentage of Participants With Dose Limiting Toxicities (DLTs)	Up to 28 days after first CNTY-101 infusion
Recommended Phase 2 Regimen (RP2R) of CNTY-101 With/Without IL-2 (With or Without Optimized LDC)	Up to 3 months after the first CNTY-101 infusion

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With TEAEs and Serious Adverse Events (SAEs)	Day 1 up to 1 year
Percentage of Participants With Clinically Significant Laboratory Abnormalities and Severity of Laboratory Abnormalities	Day 1 up to 1 year
Percentage of Participants With Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Severity of CRS and ICANS	Day 1 up to 1 year
Percentage of Participants With SLE - Responder Index 4 (SRI-4) Response	Up to 1 year
Percentage of Participants With Low Disease Activity by Lupus Low Disease Activity State (LLDAS)	Up to 1 year
Percentage of Participants in Remission as Measured by Definitions of Remission in SLE (DORIS) Remission	Up to 1 year
Change From Baseline in CSM Component of Manual Muscle Testing (MMT)-8 Score	Baseline up to 1 year
Change From Baseline in CSM Component of Patient Global Assessment (PtGA)	Baseline up to 1 year
Change From Baseline in CSM Component of Physician Global Assessment (PhGA)	Baseline up to 1 year
Change From Baseline in CSM Component of Muscle Enzyme Levels	Baseline up to 1 year
Change From Baseline in CSM Component of Health Assessment Questionnaire- Disability Index (HAQ-DI) Score	Baseline up to 1 year
Change From Baseline in CSM Component of Extramuscular Assessment by Myositis Disease Activity Assessment Tool (MDAAT)	Baseline up to 1 year
For Participants With ILD: Time to Progression in Interstitial Lung Disease (ILD)	Up to 1 year
For Participants With ILD: Percentage of Participants With Progression in ILD	Up to 1 year
For Participants With ILD: Change in Participant Reported Dyspnea Over Time as Measured by University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)	Up to 1 year
Change in American College of Rheumatology Combined Response in Diffuse Cutaneous Systemic Sclerosis (ACR-CRISS) Scores	Up to 1 year
Percentage of Responders as Measured by ACR-CRISS Score	Up to 1 year
Change From Baseline in ACR-CRISS Scores	Baseline up to 1 year
Change From Baseline in Fibrosing Skin Disease Based on Modified Rodnan Skin Score (mRSS)	Baseline up to 1 year
Percentage of Participants With Total Improvement Score (TIS) ≥20, ≥40, and ≥60	Up to 1 year
Mean TIS	Baseline up to 1 year
Change From Baseline in Each Core Set Measures (CSM)	Baseline up to 1 year
For Participants With Interstitial Lung Disease (ILD): Time to Improvement in Forced Vital Capacity (FVC%) ≥10%	Up to 1 year
For Participants With ILD: Percentage of Participants With Improvement in FVC% ≥10%	Up to 1 year
For Participants with ILD: Change From Baseline in Percent FVC (%FVC)	Baseline up to 1 year
For Participants With ILD: Change From Baseline in Percent Diffusion Capacity of The Lung for Carbon Monoxide (%DLCO)	Baseline up to 1 year
Change From Baseline in Scleroderma Health Assessment Questionnaire (SHAQ)	Baseline up to 1 year

Collaborators and Investigators

• Sponsor: Century Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): February 6, 2025
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2028

Study Registration Dates

• First Submitted: February 5, 2024
• First Submitted That Met QC Criteria: February 5, 2024
• First Posted (Actual): February 12, 2024

Study Record Updates

• Last Update Posted (Actual): January 8, 2026
• Last Update Submitted That Met QC Criteria: January 6, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Lupus; SLE; Myositis; Dermatomyositis; Systemic Lupus Erythematosus; Autoimmune disease; Polymyositis; Idiopathic Inflammatory Myopathies; IIM; Lupus Nephritis; Systemic sclerosis; Cellular therapy; CNTY-101; CAR NK; Sclerosis; Anti-synthetase syndrome; CAR iNK; Induced pluripotent stem cell (iPSC); Anti-CD19 therapy; Diffuse Cutaneous Systemic Sclerosis; DcSSc
• Additional Relevant MeSH Terms: Urogenital Diseases; Musculoskeletal Diseases; Nervous System Diseases; Muscular Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neuromuscular Diseases; Connective Tissue Diseases; Immune System Diseases; Skin Diseases; Glomerulonephritis; Nephritis; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Lupus Erythematosus, Systemic; Sclerosis; Lupus Nephritis; Autoimmune Diseases; Scleroderma, Systemic; Scleroderma, Diffuse; Dermatomyositis; Polymyositis; Myositis; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors; Intercellular Signaling Peptides and Proteins; Cytokines; Interleukins; Lymphokines; Interleukin-2
• Other Study ID Numbers: CNTY-101-151-01; 2024-518797-13 (Other Identifier: Clinical Trial Register (CTR) Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No